Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.

Abstract: Methods of treating or reducing risk of aneurysm, reducing cardiovascular risk, reducing serum cholesterol, reducing serum triglycerides, and/or reducing atherosclerotic plague in a subject involve administering to the subject an effective amount of a 5HT3R antagonist.

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of cocaine use by a cocaine use disorder patient; in preventing relapse into cocaine use by a cocaine use disorder patient; in the promotion of cocaine abstinence by a cocaine use disorder patient; in in the treatment of the symptoms of depression or anxiety associated with cocaine use disorder.

Abstract: A composition and a method of washing urushiol off the surface of human skin. The composition includes a first solely C12 surfactant and a second solely C12 surfactant that are each in a non-buffered composition and the composition is free of each of the following: (1) any nonylphenol ethoxylate, (2) any pharmaceutically active drug or prodrug, or (3) any salt that affects the functional characteristics of either of the solely C12 surfactants.

Abstract: Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Abstract: This disclosure describes various reaction vessel configurations that include a housing component; a reaction chamber defined by the housing component; and a light absorbing layer conforming to a portion of an interior-facing surface of the housing component that defines the reaction chamber, the light absorbing layer comprising multiple discrete regions. An energy source may direct light at one or more of the discrete regions of the light absorbing layer so as to heat the discrete regions and ultimately heat a solution within a reaction chamber.

Abstract: A power conversion device includes a power conversion circuit and a power conversion control circuit. The power conversion control circuit is configured to calculate a positive-phase sequence current command signal based on a positive-phase sequence voltage of the three-phase AC output voltage and a positive-phase sequence current of the three-phase AC output current, calculate a negative-phase sequence current command signal based on the first axis negative-phase sequence current command value, the second axis negative-phase sequence current command value, the first axis negative-phase sequence current value, and the second axis negative-phase sequence current value, and generate the switching control signal based on the positive-phase sequence current command signal and the negative-phase sequence current command signal.

Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Abstract: The present disclosure relates to compositions comprising insulin and to be administered rectally for treatment of inflammatory bowel diseases and inflammation-induced colorectal tumour and/or cancer.

Abstract: Some embodiments are directed to a pharmaceutical composition including a biocompatible polymer in association with a eukaryotic cell, a platelet extract and/or lysate, or a growth factor, to be used as a drug for the prevention and/or treatment of tissue lesions. Some other embodiments are also directed to a pharmaceutical kit which includes a biocompatible polymer in association with a eukaryotic cell for the prevention and/or treatment of tissue lesions. Some other embodiments are also directed to the use of a pharmaceutical composition including a biocompatible polymer in association with a eukaryotic cell, a platelet extract and/or lysate, or a growth factor, for manufacturing a drug for the treatment of tissue lesions. Some other embodiments can be used in particular in the veterinary and pharmaceutical fields.

Abstract: The present disclosure describes systems, methods, and non-transitory computer readable media for generating and providing a causal-graph interface that visually depicts causal relationships among dimensions and represents uncertainty metrics for such relationships as part of a streamlined visualization of a causal graph. The disclosed systems can determine causality among dimensions of multidimensional data and determine uncertainty metrics associated with individual causal relationships. Additionally, the disclosed system can generate a visual representation of a causal graph with nodes arranged in stratified layers and can connect the layered nodes with uncertainty-aware-causal edges to represent both the causality between the dimensions and the uncertainty metrics.

Abstract: This disclosure relates to the use of miRNA-483 and its target genes, UBE2C, pVHL and HIF1alpha, in managing the treatment of cardiovascular and inflammatory diseases. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a miR-483 mimic and/or an HIF inhibitor and a pharmaceutically acceptable excipient for use in treating or preventing a vascular disease or condition. In certain embodiments, the miR-483 mimic is a double stranded nucleobase polymer or an expression vector that expresses mature human miR-483-5p and miR-483-3p sequences or operable fragments and variants.

Abstract: This disclosure provides non-naturally occurring collagen and elastin molecules. The non-naturally occurring collagens and elastins include truncated collagens, truncated elastins, as well as fusion proteins thereof. The non-naturally occurring collagen and elastin are useful in foods, cosmetics and many other products and uses.

Abstract: Provided are a processing method and a processing apparatus for efficacy of a combined drug. The processing method includes: obtaining dose-effect curve band of expected additive effect of the combined drug; obtaining actual dose-effect relationship curve formed by actual effect value of the combined drug with a dose change of one target component drug in the combined drug; comparing a positional relationship between the actual dose-effect relationship curve and the dose-effect curve band; and outputting the efficacy of the combined drug as a synergistic effect when the actual dose-effect relationship curve is located above the dose-effect curve band, outputting the efficacy of the combined drug as an antagonistic effect when the actual dose-effect relationship curve is located below the dose-effect curve band, and outputting the efficacy of the combined drug as an additive effect when the actual dose-effect relationship curve is located within a range of the dose-effect curve band.

Abstract: A composition and a method of washing urushiol off the surface of human skin. The composition includes a first solely C12 surfactant and a second solely C12 surfactant that are each in a non-buffered composition and the composition is free of each of the following: (1) any nonylphenol ethoxylate, (2) any pharmaceutically active drug or prodrug, or (3) any salt that affects the functional characteristics of either of the solely C12 surfactants.

Abstract: A composition comprises a low-solubility ingredient having a particle size of at most 10 ?m dispersed in a solvent. The ingredient is present in an amount greater than the saturation limit of the ingredient in the solvent. The composition passes the freeze-thaw cycling test.

Abstract: Provided are fusion proteins between p97 (melanotransferrin) and iduronate-2-sulfatase (IDS), and related compositions and methods of use thereof, for instance, to facilitate delivery of IDS across the blood-brain barrier (BBB) and/or improve its tissue penetration in CNS and/or peripheral tissues, and thereby treat and/or diagnose Hunter Syndrome (Mucopolysaccharidosis type II; MPS II) and related lysosomal storage disorders, including those having a central nervous system (CNS) component.

Abstract: The invention relates to therapeutic applications for compositions that reduce the level of oxidative stress on cells in vivo or in vitro. The invention describes methods for improving the therapeutic properties of stem cells. The invention also provides combination therapies that are useful to balance the oxidative microenvironment of cells in vivo or in vitro.

Abstract: Methods of treating a condition resulting in nociceptive pain are provided. The method includes the step of administering to a mammal a therapeutically effective amount of a compound selected from the group consisting of diacetyl salicylic acid (DAS), aurin tricarboxylic acid (ATA), aurin quadracarboxylic acid (AQA), aurin hexacarboxylic acid (AHA), and/or a combination thereof.

Abstract: Described herein is a novel cyclotide able to activate the unique receptor of angiotensin-(1-7) (AT1-7), the MAS1 receptor. This cyclotide may be used in the treatment of cancer and myocardial infarction.

Abstract: Compositions and methods for modulating HIF-2? to meditate of hypoxia signaling in satellite cells and applications thereof for improving skeletal muscle generation and repair are provided. For example, methods of enhancing, increasing, accelerating or/and otherwise improving skeletal muscle generation or regeneration in a subject in need thereof are disclosed. In some embodiments, the methods include administering the subject an effective amount of HIF-2? inhibitor. The HIF-2? inhibitor can be effective to, for example, increase muscle satellite cell proliferation, differentiation, or a combination thereof in a subject. Composition and methods for improving respiration, and reducing or preventing the development or progression of fibrosis are also provided. The disclosed compositions and methods are particularly useful for treating muscular dystrophies, myopathies, and other muscle-related diseases and disorders.

Abstract: In one aspect, a coronavirus is treated by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, oxidative stress is reduced in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, mitochondrial reactive oxygen species (mtROS) are inhibited in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In one example, the coronavirus is Covid-19.

Abstract: The present invention concerns methods and compositions involving inhibitors and of RAD51, a protein involved in homologous recombination. In some embodiments, there are methods for sensitizing cells to the effects of DNA damaging agents, which can have particular applications for cancer patients. In some embodiments of the invention, the RAD51 inhibitor is a small molecule that directly affects RAD51 activity, such as its ability to promote filament formation.

Abstract: This document provides methods and materials for treating HIV infections. For example, methods and materials for using one or more proteosome inhibitors in combination with one or more other agents to treat HIV infections are provided.

Abstract: The present invention relates to a composition which is for preventing and treating eye diseases and comprises an anti-angiopoietin-2 (Ang2) antibody and, more specifically, to a novel use of an anti-Ang2 antibody as an agent for preventing or treating eye diseases, wherein the anti-Ang2 antibody is specifically coupled to Ang2, is coupled to a Tie2 receptor together with Ang2, and has improved affinity. The composition according to the present invention can be usefully used to develop a treatment agent for macular degeneration, diabetic retinopathy, and glaucoma.

Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action ?-opioid receptor antagonist/?-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a ?-opioid receptor antagonist or prodrug thereof, and a ?-opioid receptor agonist or prodrug thereof can be administered, either together or separately.

Abstract: A computer-implemented method and system can include obtaining, by at least one processor, at least one visual input comprising a face of at least one person. The at least one processor can input the at least one visual input into at least one psychodiagnostic neural network (PNN) to obtain at least one personality metric of the at least one person. The at least one personality metric of the at least one person can include at least one personality dimension and at least one numerical personality score. The at least one numerical personality score may provide a numerical indication of the strength of a particular personality dimension and display at least one personality report on at least one screen of at least one computing device. The at least one personality report may include the at least one personality metric of the at least one person.

Abstract: Methods for treating a patient suffering from neural cell injury, the method comprising administering to the patient an effective amount of a HIF prolyl-4-hydroxylase inhibiting compound having the following general formula (1) wherein R1 is a cyclic group containing at least three and up to seven carbon atoms and optionally containing one or more heteroatoms selected from O, N, and S, and optionally attached to the shown carbon atom by a linking group; R2 is independently selected from said cyclic groups of R1 and acyclic hydrocarbon groups R5 containing up to twenty carbon atoms; R3 is selected from hydrogen atom and hydrocarbon groups containing up to six carbon atoms; R6 and R7 are independently selected from hydrogen atom, hydrocarbon groups containing up to three carbon atoms, halogen atom, and polar groups, as well as methylene-linked versions thereof; and t is 0 or 1.

Abstract: The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering front a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain barrier.

Abstract: The present invention provides methods for treating cancer using mGluR8 inhibitors, such as mGluR8 inhibitory antibodies and small molecules. The invention also features compositions containing mGluR8 inhibitors, methods of diagnosing patients with mGluR8-associated cancer, and methods of predicting the response of cancer in a subject to treatment with mGluR8 inhibitors.

Abstract: Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.

Abstract: This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided.

Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.

Abstract: Methods, compositions, and devices to limit, modulate, insulate, and/or otherwise alter the effects of exogenous physical stimuli on cells are described herein. The cells may be removed from the body, preferably isolated, and treated ex vivo with the composition to limit the effects of physical stimuli on the cells and then returned to the patient. Alternatively, the cells may be treated in vivo. The compositions can be administered a variety of manners, such as systemically, locally or regionally.

Abstract: The present invention provides methods and compositions for improving episodic memory and treating dementia.

Abstract: The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.

Abstract: The present invention provides a compound capable of being used as an active ingredient of an anti-cancer agent. To provide an anti-cancer agent with few side effects, an object of the present invention is to provide a compound capable of selectively inhibiting the target, i.e., DOCK1, or a salt thereof. The pyridinone compound of the present invention is represented by Formula (1): wherein R1 and R2 are the same or different, and each represents C1-6 alkyl; and R3 is a group represented by, for example, Formula (3) below: wherein R5 in the group represented by Formula (3) is hydrogen.

Abstract: The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.

Abstract: The present invention relates to an opioid antagonist with ?-activity for use in treatment of depressive disorder with melancholic features. The invention further relates to the combination of an opioid antagonist with ?-activity and vortioxetine for use in treatment of depressive disorder with melancholic features. The invention also relates to pharmaceutical compositions comprising an opioid antagonist with ?-activity and vortioxetine.

Abstract: The present invention pertains to an efficient and large-scale process to produce a medium-chain triglyceride composition with >95% content for C8 (caprylic acid), C10 (capric acid) and C12 (lauric acid), with the content of lauric acid at about 5% or more. The process involves fractionation of fatty acid methyl esters, which are mainly derived from coconut or palm kernel, their esterification to glycerol to synthesize medium-chain triglycerides, and refining them to significantly increase purity and make them fit for human consumption. Such composition can have important uses in food and its preparation, health supplements, cosmetics, and medicine, among others.

Abstract: The invention relates to therapeutic applications for compositions that reduce the level of oxidative stress on cells in vivo or in vitro. The invention describes methods for improving the therapeutic properties of stem cells. The invention also provides combination therapies that are useful to balance the oxidative microenvironment of cells in vivo or in vitro.

Abstract: A compound comprising a cyclodextrin and a monoalkoxy polyethylene glycol linked thereto through an ether bond (a “pegylated cyclodextrin”) is disclosed, as are drug delivery vehicles and pharmaceutical formulations including the same, and methods for making the compound and the drug delivery vehicle and for delivering the drug to a patient in need thereof. The method of making includes the steps of creating either a tosylated monoalkoxy polyethylene glycol or a tosylated cyclodextrin, and either reacting the tosylated monoalkoxy polyethylene glycol with a deprotonated cyclodextrin, or reacting the tosylated cyclodextrin with a deprotonated monoalkoxy polyethylene glycol. The present pegylated cyclodextrin readily forms an inclusion compound with certain drugs to protect the drug against adverse interactions with mucin (e.g., in a mucus membrane).

Abstract: H—NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H—NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H—NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H—NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.

Abstract: Described herein are a series of compounds having the structure of Formula I: for use in the inhibition of MAO and uses thereof for the treatment of a barrier disease, obesity, solid epithelial cell tumor metastasis, diabetes, an auto-immune and inflammatory disease or a cardiometabolic disorder.

Abstract: The invention relates to diagnosis, detection, screening, identifying and predicting methods. In various embodiments, methods of the invention include diagnosis, detection, or screening for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject; identifying a subject that will or is likely to respond to a therapy for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia); and predicting therapeutic efficacy of a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) treatment in a subject.

Abstract: The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoacetonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.

Abstract: The present invention pertains to antibodies against a novel isoform of human PD1 protein (?42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against ?42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against ?42PD1 are monoclonal.

Abstract: The present disclosure highlights the relationship between extracellular mitochondrial components, optionally in combination with the secreted phospholipase A2-IIA and/or an auto-antibody, and in vivo as well as in vitro and inflammatory reactions/conditions, especially those released as a result of the degradation of a platelet. The present disclosure provides methods for determining the presence of inflammatory mediators, for limiting inflammatory reactions/conditions, for the diagnosis inflammatory reactions/conditions, for screening therapeutics for the treatment and/or the alleviation of symptoms of inflammatory reactions/conditions based on the detection or modulation of the level of these extracellular mitochondrial components.